Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 23;3:PO.18.00365. doi: 10.1200/PO.18.00365

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

FIG 2. — Biomarker selection through GeneTerrain visualization tools shown in a two-dimensional (2D) panel. (A) Intact-protein analysis system (IPAS)-01: GeneTerrain visualization shown in 2D for the graft-versus-tumor (GVT) signature obtained by comparing GVT-positive, graft-versus-host disease (GVHD)–negative with GVT-positive, GVHD-positive post–donor lymphocyte injection (DLI) samples. The nodes between genes represent the protein-protein interaction pairs from the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database. The protein-protein interaction confidence score in STRING contains functional protein associations derived from in-house predictions and homology transfers as well as from several externally maintained databases. Each interaction is assigned a score between 0 and 1, which is meant to be the probability that the interaction really exists given the available evidence. (B) IPAS-02: GeneTerrain visualization shown in 2D for the GVT signature from the pre- and post-DLI comparison. (C) Combined IPAS-01 and IPAS-02: GeneTerrain visualization shown in 2D for GVT without GVHD from both analyses.